Xeno Biosciences
Somerville
About Xeno Biosciences
Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery. It was founded in 2015 and is headquartered in Somerville, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.8M
- Funding stage: M&A
- Last round: Debt Financing (Jan 2023)
- Website: xenobiosciences.com
- Phone: 714-715-0970
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/xeno-biosciences-33525 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.